Clinical course and outcome after kidney transplantation in patients with C3 glomerulonephritis due to CFHR5 nephropathy
| Autor: | Frangou, Eleni, Varnavidou-Nicolaidou, Agathi, Petousis, Panayiotis, Soloukides, Andreas, Theophanous, Elena, Savva, Isavella, Michael, Nicos, Toumasi, Elpida, Georgiou, Dora, Stylianou, Galatia, Mean, Richard, Anastasiadou, Natasa, Athanasiou, Yiannis, Zavros, Michalis, Kyriacou, Kyriacos, Deltas, Constantinos, Hadjianastassiou, Vassilis |
|---|---|
| Přispěvatelé: | Deltas, Constantinos [0000-0001-5549-9169] |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty 030232 urology & nephrology Urology 030204 cardiovascular system & hematology Nephropathy 03 medical and health sciences 0302 clinical medicine Glomerulonephritis medicine Humans Survival rate Kidney transplantation Aged Retrospective Studies Transplantation Proteinuria business.industry Complement System Proteins Middle Aged medicine.disease Prognosis Kidney Transplantation 3. Good health Survival Rate Nephrology Mutation CFHR5 nephropathy Female Kidney Diseases medicine.symptom business CFHR5 |
| Zdroj: | Nephrology Dialysis Transplantation Nephrol Dial Transplant |
| Popis: | Background Complement factor H-related protein 5 (CFHR5) nephropathy is an inherited renal disease characterized by microscopic and synpharyngitic macroscopic haematuria, C3 glomerulonephritis and renal failure. It is caused by an internal duplication of exons 2–3 within the CFHR5 gene resulting in dysregulation of the alternative complement pathway. The clinical characteristics and outcomes of transplanted patients with this rare familial nephropathy remain unknown. Methods This is a retrospective case series study of 17 kidney transplant patients with the established founder mutation, followed-up over a span of 30 years. Results The mean (±SD) age of patients at the time of the study and at transplantation was 58.6 ± 9.9 and 46.7 ± 8.8 years, respectively. The 10- and 15-year patient survival rates were 100 and 77.8%, respectively. Proteinuria was present in 33.3% and microscopic haematuria in 58.3% of patients with a functional graft. Serum complement levels were normal in all. ‘Confirmed’ and ‘likely’ recurrence of CFHR5 nephropathy were 16.6 and 52.9%, respectively; however, 76.5% of patients had a functional graft after a median of 120 months post-transplantation. Total recurrence was not associated with graft loss (P = 0.171), but was associated with the presence of microscopic haematuria (P = 0.001) and proteinuria (P = 0.018). Graft loss was associated with the presence of proteinuria (P = 0.025). Conclusions We describe for the first time the clinical characteristics and outcome of patients with CFHR5 nephropathy post-transplantation. Despite the recurrence of CFHR5 nephropathy, we provide evidence for a long-term favourable outcome and support the continued provision of kidney transplantation as a renal replacement option in patients with CFHR5 nephropathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|